Profound lymphopenia is associated with a lower risk of hepatic cytolysis during antithymocyte globulin administration

Am J Hematol. 2016 Jun;91(4):E276-8. doi: 10.1002/ajh.24309.

Authors

Bashar Al Dweik¹, Rabah Redjoul¹, Sylvie Bastuji-Garin^{2

3}, Florence Beckerich^{1

4}, Christine Robin^{1

4}, Cécile Pautas¹, Andréa Toma¹, Ludovic Cabanne¹, Sébastien Maury^{1

4}, Catherine Cordonnier^{1

4}

Affiliations

¹ Department of Hematology, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Creteil, France.
² Department of Public Health, AP-HP, Henri Mondor Teaching Hospital, Créteil, France.
³ CEpiA (Clinical Epidemiology and Ageing) Unit EA 7376, UPEC, DHU A-TVB, IMRB, Créteil, France.
⁴ Paris-Est Créteil University (UPEC), Créteil, France.

PMID: 26799506
DOI: 10.1002/ajh.24309

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antilymphocyte Serum / administration & dosage*
Antilymphocyte Serum / adverse effects*
Humans
Immunosuppressive Agents / administration & dosage*
Immunosuppressive Agents / adverse effects*
Incidence
Lymphopenia / epidemiology*
Lymphopenia / etiology*
Risk Factors
Time Factors

Substances

Antilymphocyte Serum
Immunosuppressive Agents